Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer

Clinical Breast Cancer

Volumn 14, Issue 1, 2014, Pages 20-25

  McVeigh, Terri Patricia ^a   Al Azawi, Dhafir ^a   Kearney, David E ^a   Malone, Carmel ^a   Sweeney, Karl J ^a   Barry, Kevin ^a   McLaughlin, Ray ^a   Keane, MacCon ^a   Kerin, Michael J ^a  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

Axilla; Breast cancer; HER2; Neoadjuvant chemotherapy; Pathologic response

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

AXILLA; BREAST CANCER; HER2; NEOADJUVANT CHEMOTHERAPY; PATHOLOGIC RESPONSE;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 84892807383     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.08.017     Document Type: Article

References (33)

1. M. Kaufmann, G. von Minckwitz, and H.D. Bear et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 18 2007 1927 1934
2. J.R. Gralow, H.J. Burstein, and W. Wood et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 2008 814 819
3. C. Shannon, and I. Smith Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45 2003 77 90
4. J. Huober, and G. Von Minckwitz Neoadjuvant therapy - what have we achieved in the last 20 years Breast Care 6 2011 419 426
5. C.H.M. van Deurzen, B.E. Vriens, and V.C. Tjan-Heijnen et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review Eur J Cancer 45 18 2009 3124 3130
6. K. Shimazu, and S. Noguchi Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer Surg Today 41 2011 311 316
7. B. Zhou, F. Xie, and D. Yang Molecular subtypes as predictive factors for response to neoadjuvant chemotherapy in breast cancer patients Chinese J Clin Oncol 36 2009 199 202 206
8. L.J. Esserman, D.A. Berry, and A. DeMichele et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: fesults from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657 J Clin Oncol 30 2012 3242 3249
9. G. von Minckwitz Neoadjuvant chemotherapy in breast cancer - insights from the German experience Breast Cancer 2012 1 7
10. N. Houssami, P. Macaskill, and G. von Minckwitz et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy Eur J Cancer 48 2012 3342 3354
11. A. Lucci, L.M. McCall, and P.D. Beitsch et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011 J Clin Oncol 25 2007 3657 3663
12. R.E. Mansel, L. Fallowfield, and M. Kissin et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial J Natl Cancer Inst 98 9 2006 599 609
13. G. Gill Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial Ann Surg Oncol 16 2009 266 275
14. T. Ashikaga, D.N. Krag, and S.R. Land et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection J Surg Oncol 102 2010 111 118
15. A.E. Giuliano, K.K. Hunt, and K.V. Ballman et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial JAMA 305 2011 569 575
16. G.H. Lyman, A.E. Guiliano, and M.R. Somerfield et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol 23 2005 7703 7720
17. G.F. Schwartz, A.E. Giuliano, and U. Veronesi Conensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania Cancer 94 2002 2542 2551
18. S. Buys, and T. Yankeelov NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis J Natl Compr Canc Netw 7 2009 1060 1096 J Natl Compr Canc Netw 2010;8:2
19. R.W. Carlson, DC Allred, and BO Anderson et al. Invasive breast cancer: Clinical practice guidelines in oncology J Natl Compr Canc Netw 9 2011 136 222
20. B. Fisher, A. Brown, and E. Mamounas et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 1997 2483 2493
21. H.M. Kuerer, A.A. Sahin, and K.K. Hunt et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy Ann Surg 230 1999 72 78
22. M.Z. Papa, D. Zippel, and B. Kaufman et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer J Surg Oncol 98 2008 403 406
23. L.F. Cohen, T.M. Breslin, and H.M. Kuerer et al. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy Am J Surg Pathol 24 2000 1266 1272
24. K.S. Nason, B.O. Anderson, and D.R. Byrd et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma Cancer 89 2000 2187 2194
25. P. Schrenk, C. Tausch, and S. Wölfl et al. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes Am J Surg 196 2008 176 183
26. V. Stearns, C.A. Ewing, and R. Slack et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer Ann Surg Oncol 9 2002 235 242
27. H. Curé, S. Amat, and F. Penault-Llorca et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy Breast Cancer Res Treat 76 2002 37 45
28. R. Rouzier, J.M. Extrra, and J. Klijanienko et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 2002 1304 1310
29. National Comprehensive Cancer Network (NCCN) guidelines, 2012. Available at: http://www.nccn.org. Accessed: September 25, 2013.
30. T. Nemoto, J. Vana, and R.N. Bedwani Management and survival of female breast cancer: results of a national survey by the American College of Surgeons Cancer 45 1980 2917 2924
31. C.L. Carter, C. Allen, and D.E. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181 187
32. M.J. Silverstein, K.A. Skinner, and T.J. Lomis Predicting axillary nodal positivity in 2282 patients with breast carcinoma World J Surg 25 2001 767 772
33. M.R. Kell, J.P. Burke, and M. Barry et al. Outcome of axillary staging in early breast cancer: a meta-analysis Breast Cancer Res Treat 120 2010 441 447